Addressing Posttreatment Selection Bias in Comparative Effectiveness Research, Using Real-World Data and Simulation.
Acute Coronary Syndrome
/ complications
Adult
Aged
Clopidogrel
/ therapeutic use
Comparative Effectiveness Research
Computer Simulation
Female
Hospitalization
/ statistics & numerical data
Humans
Intention to Treat Analysis
Latent Class Analysis
Male
Middle Aged
Myocardial Infarction
/ etiology
Platelet Aggregation Inhibitors
/ therapeutic use
Selection Bias
Stroke
/ etiology
Ticagrelor
/ therapeutic use
Treatment Outcome
Treatment Switching
acute coronary syndrome
clopidogrel
comparative effectiveness research
selection bias
simulation
ticagrelor
Journal
American journal of epidemiology
ISSN: 1476-6256
Titre abrégé: Am J Epidemiol
Pays: United States
ID NLM: 7910653
Informations de publication
Date de publication:
24 01 2022
24 01 2022
Historique:
received:
21
10
2020
revised:
23
08
2021
accepted:
28
09
2021
pubmed:
7
10
2021
medline:
5
3
2022
entrez:
6
10
2021
Statut:
ppublish
Résumé
To examine methodologies that address imbalanced treatment switching and censoring, 6 different analytical approaches were evaluated under a comparative effectiveness framework: intention-to-treat, as-treated, intention-to-treat with censor-weighting, as-treated with censor-weighting, time-varying exposure, and time-varying exposure with censor-weighting. Marginal structural models were employed to address time-varying exposure, confounding, and possibly informative censoring in an administrative data set of adult patients who were hospitalized with acute coronary syndrome and treated with either clopidogrel or ticagrelor. The effectiveness endpoint included first occurrence of death, myocardial infarction, or stroke. These methodologies were then applied across simulated data sets with varying frequencies of treatment switching and censoring to compare the effect estimate of each analysis. The findings suggest that implementing different analytical approaches has an impact on the point estimate and interpretation of analyses, especially when censoring is highly unbalanced.
Identifiants
pubmed: 34613378
pii: 6382168
doi: 10.1093/aje/kwab242
doi:
Substances chimiques
Platelet Aggregation Inhibitors
0
Clopidogrel
A74586SNO7
Ticagrelor
GLH0314RVC
Types de publication
Evaluation Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
331-340Informations de copyright
© The Author(s) 2021. Published by Oxford University Press on behalf of the Johns Hopkins Bloomberg School of Public Health. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.